NURS 684 — Exam 3 Review
Latest Update • 40 Questions & Answers
QUESTION
1
T/F? Bone density is recommended in all women 2 years post-menopause.
ANSWER
FALSE
– Baseline screening starts at age 65 and older.
QUESTION
2
A 52-year-old woman presents with amenorrhea for one year and moderate hot
flashes for 6 months. She is interested in bioidentical hormone relief.
Appropriate info to provide?
ANSWER
17 beta-estradiol is a bioidentical form of estrogen available in oral, transdermal, and
vaginal formulations.
QUESTION
3
Which statement concerning the estrogen agonist/antagonist raloxifene (Evista)
is correct?
ANSWER
It is approved for the prevention AND treatment of osteoporosis.
QUESTION
4
T/F? Data supports the use of topically applied progesterone creams for
endometrial protection in menopausal women taking estrogen.
ANSWER
FALSE
, QUESTION
5
What would NOT be an expected finding in a pelvic examination of a 70-year-old
woman?
ANSWER
Ovaries easily palpable. (Ovaries atrophy after menopause and should NOT be
palpable.)
QUESTION
6
A menopausal woman asks about vaginal lubricant vs. vaginal moisturizer. What
would NOT be a true statement?
A. Lubricants reduce friction related to sex
B. Lubricants take several weeks before becoming effective
C. Moisturizers provide longer-term relief than lubricants
D. Moisturizers are typically applied several times weekly
ANSWER
B. (INCORRECT statement) — Lubricants are effective IMMEDIATELY, not after
several weeks.
QUESTION
7
T/F? Data supports the use of hormonal therapy for prevention of cognitive
decline if started soon after menopause.
ANSWER
FALSE
QUESTION
8
An advantage of the transdermal patch over oral delivery of estrogen for
menopausal symptoms is that the transdermal delivery method ___.
ANSWER
Has LESS adverse effects on coagulation factors (bypasses first-pass hepatic
metabolism).
Latest Update • 40 Questions & Answers
QUESTION
1
T/F? Bone density is recommended in all women 2 years post-menopause.
ANSWER
FALSE
– Baseline screening starts at age 65 and older.
QUESTION
2
A 52-year-old woman presents with amenorrhea for one year and moderate hot
flashes for 6 months. She is interested in bioidentical hormone relief.
Appropriate info to provide?
ANSWER
17 beta-estradiol is a bioidentical form of estrogen available in oral, transdermal, and
vaginal formulations.
QUESTION
3
Which statement concerning the estrogen agonist/antagonist raloxifene (Evista)
is correct?
ANSWER
It is approved for the prevention AND treatment of osteoporosis.
QUESTION
4
T/F? Data supports the use of topically applied progesterone creams for
endometrial protection in menopausal women taking estrogen.
ANSWER
FALSE
, QUESTION
5
What would NOT be an expected finding in a pelvic examination of a 70-year-old
woman?
ANSWER
Ovaries easily palpable. (Ovaries atrophy after menopause and should NOT be
palpable.)
QUESTION
6
A menopausal woman asks about vaginal lubricant vs. vaginal moisturizer. What
would NOT be a true statement?
A. Lubricants reduce friction related to sex
B. Lubricants take several weeks before becoming effective
C. Moisturizers provide longer-term relief than lubricants
D. Moisturizers are typically applied several times weekly
ANSWER
B. (INCORRECT statement) — Lubricants are effective IMMEDIATELY, not after
several weeks.
QUESTION
7
T/F? Data supports the use of hormonal therapy for prevention of cognitive
decline if started soon after menopause.
ANSWER
FALSE
QUESTION
8
An advantage of the transdermal patch over oral delivery of estrogen for
menopausal symptoms is that the transdermal delivery method ___.
ANSWER
Has LESS adverse effects on coagulation factors (bypasses first-pass hepatic
metabolism).
